作者：常琪1 ，马飒飒1 ，李占标1 ，袁欣1 ，孙静茹2

单位：

1.252000山东省聊城市人民医院疼痛科　2.252000山东省聊城市人民医院质控科

Units：

1.Department of Pain, Liaocheng People's Hospital, Liaocheng 252000, China 2.Quality Control Department, Liaocheng People's Hospital, Liaocheng 252000, China

关键词：

肺肿瘤；肿瘤转移；骨转移；miR-154-5p

Keywords：

　Lung neoplasms; Neoplasm metastasis; Bone metastasis; miR-154-5p

CLC：

R 734.2

DOI：

10.12114/j.issn.1008-5971.2024.00.098

Funds：

山东省卫生健康科研基金项目（20200126）

摘要：

目的　探讨miR-154-5p对肺癌骨转移的影响。方法　本实验时间为2021年9月—2022年2月。选取 BALB/c-nu小鼠60只，采用随机数字表法将小鼠分为载体组和miR-154-5p组，每组30只。将pMSCV puro反转录病毒 载体或过表达miR-154-5p的A549细胞分别注入载体组、miR-154-5p组小鼠左心室。注药第80天，载体组剩余6只存 活，miR-154-5p组剩余21只存活。载体组取6只小鼠，miR-154-5p组随机取6只小鼠，用于后期数据分析。注药第0、 20、40、60、80天采用缩爪阈值评估小鼠机械性疼痛程度，注药第80天进行X线检查以评价小鼠骨转移评分，注药 第80天采用苏木精-伊红染色检测溶骨性病变面积。从注药开始每天监测两组小鼠生存情况和无骨转移生存情况，连 续记录80 d。结果　干预方法与时间在缩爪阈值上存在交互作用（P＜0.05），干预方法、时间在缩爪阈值上主效应 显著（P＜0.05）；注药第40、60、80天，miR-154-5p组缩爪阈值高于载体组（P＜0.05）。注药第80天，miR-154- 5p组骨转移评分低于载体组，溶骨性病变面积小于载体组（P＜0.05）。载体组生存率为20%，miR-154-5p组生存 率为70.0%。miR-154-5p组生存率高于载体组（P＜0.05）。载体组中位无骨转移生存期为35 d，无骨转移生存率为 86.7%；miR-154-5p组中位无骨转移生存期为76 d，无骨转移生存率为50.0%。miR-154-5p组无骨转移生存率高于载 体组（P＜0.05）。结论　miR-154-5p上调可提高肺癌小鼠的缩爪阈值，抑制骨转移，并延长小鼠生存期和无骨转移 生存期。

Abstract：

　Objective To investigate the effect of miR-154-5p on bone metastasis in lung cancer. Methods Experimental time of this study was from September 2021 to February 2022. Sixty BALB/c-nu mice were selected and divided into carrier group and miR-154-5p group using a random number table method, with 30 mice in each group. The pMSCV puro retrovirus vector or A549 cells overexpressing miR-154-5p were injected into the left ventricle of mice in carrier group and miR- 154-5p group, respectively. On the 80th day of drug injection, 6 mice in the carrier group survived and 21 mice in the miR- 154-5p group survived. Six mice were selected from the carrier group and six mice were randomly selected from the miR-154- 5p group for later data analysis. On the 0th, 20th, 40th, 60th and 80th day of drug injection, the degree of mechanical pain in mice was evaluated by paw withdrawal threshold; on the 80th day of drug injection, the bone metastasis score was evaluated by X-ray examination, and the osteolytic lesion area was detected by hematoxylin eosin staining. The survival and bone metastasis free survival of mice were monitored every day for 80 days. Results There was an interaction between intervention methods and time on the paw withdrawal threshold (P < 0.05) , both intervention methods and time produced significant main effects on the paw withdrawal threshold (P < 0.05) . On the 40th, 60th and 80th day of drug injection, the paw withdrawal threshold in miR-154-5p group was higher than that in carrier group (P < 0.05) . On the 80th day of drug injection, the bone metastasis score in miR-154- 5p group was lower than that in carrier group, and osteolytic lesion area was smaller than that in carrier group (P < 0.05) . The overall survival rate of carrier group was 20.0%, the overall survival rate of miR-154-5p group was 70.0%. The survival rate in miR-154-5p group was higher than that in carrier group (P < 0.05) . The median bone metastasis-free survival time in the carrier group was 35 days, and the bone metastasis-free survival rate was 86.7%. The median bone metastasis-free survival time in the miR-154-5p group was 76 days, and the bone metastasis-free survival rate was 50.0 %. The bone metastasis-free survival rate in miR-154-5p group was higher than that in carrier group (P < 0.05) . Conclusion Upregulation of miR-154-5p can increase the paw withdrawal threshold of lung cancer mice, reduce the bone metastasis, and prolong the survival time and bone metastasis-free survival time.

ReferenceList：